Analyst Consensus ?
ConsensusHold13 ratings
Bullish430.8%
Neutral861.5%
Bearish17.7%
Viatris Inc. · VTRS · FY2026 Q1 · Calendar Q2 2026
Viatris Beats Q1 Estimates as Greater China Surges 18% and Pipeline Advances
Viatris posted a Q1 beat with revenue of $3.52B and EPS of $0.59, driven by 18% YoY growth in Greater China and new product contributions. The pipeline advanced with EFFEXOR's Japan approval and progress toward FDA decisions on XULANE LO and fast-acting meloxicam. Management reaffirmed 2026 guidance and emphasized disciplined capital allocation with $2.5B in cash. The stock initially surged 9.3% before drifting back roughly 8.7%, suggesting investors are weighing whether China momentum and pipeline execution are sustainable against policy and supply risks.
Reported Before market openNASDAQHealthcare
$20.68B market cap
100quality score
Company context
Snapshot as of publicationViatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors.…
Earnings scorecard
Reported versus consensus
Reported EPS
$0.59
Consensus $1
EPS surprise
+17.5%
Reported versus consensus
Reported revenue
$3.52B
Consensus $3.36B
Revenue surprise
+4.8%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$17.76Current
$12Low
$16.22Average
$22High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | May 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 8, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 8, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Jan 28, 2026 |
| Argus Research | Buy | Hold | Upgrade | Jan 16, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 7, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Feb 28, 2025 |
| BMO Capital | Market Perform | Outperform | Downgrade | Feb 17, 2023 |
| UBS | Neutral | Sell | Upgrade | Nov 10, 2022 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 12, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Mar 10, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 1, 2022 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Mar 10, 2021 |
Named analyst price targets
Upside is calculated against the persisted current price $17.76. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Glen Santangelo | $22 | $16.5 | +23.9% | May 19, 2026 |
| Truist Financial | Analyst unavailable | $20 | $16.94 | +12.6% | May 8, 2026 |
| UBS | Ashwani Verma | $18 | $14.58 | +1.4% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $12 | $13.12 | -32.4% | Jan 28, 2026 |
| Argus Research | Analyst unavailable | $15 | $12.84 | -15.5% | Jan 16, 2026 |
| Truist Financial | Les Sulewski | $16 | $12.4 | -9.9% | Jan 7, 2026 |
| Truist Financial | Analyst unavailable | $15 | $9.93 | -15.5% | Oct 15, 2025 |
| Jefferies | Glen Santangelo | $15 | $11.77 | -15.5% | Jul 19, 2024 |
| Piper Sandler | David Amsellem | $13 | $11.83 | -26.8% | Mar 28, 2024 |
| Piper Sandler | David Amsellem | $10 | $9.84 | -43.7% | Jun 26, 2023 |
| Barclays | Analyst unavailable | $15 | $12.16 | -15.5% | Feb 1, 2023 |
| UBS | Ashwani Verma | $12 | $10.83 | -32.4% | Nov 9, 2022 |
| UBS | Ashwani Verma | $9 | $10.77 | -49.3% | Jun 13, 2022 |
Track every rating change on VTRS the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+9.0%
Event window
SPY move
-0.3%
Same window
Abnormal move
+9.3%
Stock minus SPY
Volume
3.2×
Versus trailing sessions
Subsequent drift
-8.7%
Up to 20 sessions
VTRSSPY benchmark
Follow VTRS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Revenue of $3.52B beat consensus by 4.8% and EPS of $0.59 exceeded estimates by 17.5%. Greater China grew 18% YoY with e-commerce sales doubling, while new products including Creon and iron sucrose contributed $71M in revenue. The stock rose 9.3% on the report at 3.2x normal volume but subsequently drifted back approximately 8.7%.
Guidance delta
Management maintained full-year 2026 guidance, consistent with the prior quarter. The cost-savings program targeting $120M in 2026 remains on track. Capital allocation priorities -- dividends, share repurchases, and selective in-market acquisitions -- are unchanged, supported by $2.5B in cash.
Key takeaways
- Q1 revenue of $3.52B and adjusted EBITDA of approximately $1.0B both beat consensus, with Greater China growing 18% YoY.
- EFFEXOR received approval in Japan for generalized anxiety disorder; FDA decisions for XULANE LO and fast-acting meloxicam are pending.
- E-commerce sales in Greater China doubled year-over-year, signaling accelerating commercial execution.
- Cost-saving initiatives targeting $120M in 2026 remain on track, supporting EBITDA margin expansion.
- Management reaffirmed 2026 guidance with $2.5B in cash available for dividends, buybacks, and strategic investments.
Management priorities
- Launch XULANE LO in the US by July 2026
- Seek FDA approval and launch fast-acting meloxicam by year-end 2026
- Commercialize EFFEXOR and pitolisant in Japan and pursue additional indications
- Deliver pipeline readouts for Nefecon, selatogrel, and cenerimod in 2026-2027
- Continue cost-saving initiatives targeting $120M in 2026
- Deploy cash through dividends, share repurchases, and selective in-market acquisitions
Related earnings events
HealthcareHCA · FY2026 Q2 · Calendar Q3 2026HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex UnveiledWST · FY2026 Q2 · Calendar Q3 2026West Pharmaceutical Q2 2026: EPS and Revenue Beat, Guidance Raised AgainDGX · FY2026 Q2 · Calendar Q3 2026Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T02:51:34.687298+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T02:51:34.684457+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.